Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ion Beam ApplicationsIOBCF 81 3-Year EBITDA Growth Rate is 43.40% as of Dec. 2025. GuruFocus rates IOBCF with a GF Score™ of 81/100 and a GF Value™ of $18.56 (Fairly Valued). The stock has 10 warning signs investors should review. Among 694 Medical Devices & Instruments companies, Ion Beam Applications ranks better than 85.16% on this metric.
During the past 12 months, Ion Beam Applications's average EBITDA Per Share Growth Rate was 23.60% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 43.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -0.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Ion Beam Applications was 77.30% per year. The lowest was -51.60% per year. And the median was -9.35% per year.
Ion Beam Applications (OTCPK:IOBCF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Ion Beam Applications 3-Year EBITDA Growth Rate Related Terms
IOBCF vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Ion Beam Applications's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ion Beam Applications 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ion Beam Applications's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Ion Beam Applications's 3-Year EBITDA Growth Rate falls into.
Ion Beam Applications 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 43.40% mean?
Ion Beam Applications (IOBCF) has a 3-Year EBITDA Growth Rate of 43.40% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ion Beam Applications and its competitors. According to the industry distribution chart, Ion Beam Applications ranks #103 out of 694 companies in the Medical Devices & Instruments industry, placing it in the top 14.8%.
Is Ion Beam Applications' 3-Year EBITDA Growth Rate too high?
Ion Beam Applications' current 3-Year EBITDA Growth Rate is 43.40%. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.55. Ion Beam Applications' value of 43.40% is 474.8% above this industry median. Based on the distribution chart, Ion Beam Applications ranks #103 out of 694 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Ion Beam Applications has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ion Beam Applications' 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Ion Beam Applications ranks #103 out of 694 companies for 3-Year EBITDA Growth Rate. This places Ion Beam Applications in the top 15% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 7.55. Ion Beam Applications' value of 43.40% is 474.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.55, based on 694 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ion Beam Applications's current 3-Year EBITDA Growth Rate of 43.40% is 474.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ion Beam Applications and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ion Beam Applications's current 3-Year EBITDA Growth Rate is 43.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ion Beam Applications stock overvalued right now?
Based on GuruFocus' analysis, Ion Beam Applications (IOBCF) is currently considered Fairly Valued. The stock's GF Value™ is $18.56, compared to a current price of $19.18 — trading 3.3% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 43.40% and 474.8% above the Medical Devices & Instruments industry median of 7.55. Ion Beam Applications' overall GF Score™ is 81/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Ion Beam Applications (IOBCF), the current 3-Year EBITDA Growth Rate is 43.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ion Beam Applications (IOBCF) Overvalued in 2026?
Based on GuruFocus' analysis, Ion Beam Applications stock appears to be overvalued.
The current stock price of $19.18 is trading 3.3% above its estimated GF Value™ of $18.56.
GuruFocus considers Ion Beam Applications to be Fairly Valued.
Key valuation signals for IOBCF:
3-Year EBITDA Growth Rate: 43.40%
GF Value™: $18.56 vs. price of $19.18 (3.3% above fair value)
Industry Position: 474.8% above the Medical Devices & Instruments median (#103 of 694)
No single metric tells the full story. See the IOBCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ion Beam Applications SA develops and manufactures medical devices and software solutions. The firm operates in three segments: IBA Clinical, including Proton Therapy and Dosimetry; IBA Technologies; and IBA Corporate. Proton therapy and other accelerators contribute to the majority of sales. It offers solutions for precision cancer treatment through the use of proton beams, as well as cyclotrons used for the production of radioisotopes and industrial accelerators for sterilization and ionization. The dosimetry business sells measurement and quality assurance instruments for radiotherapy and medical imaging. The firm operates in three geographical areas: Belgium, the United States, China, Germany, and India.
81GF Score
Get the complete analysis for IOBCF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IOBCF has been successfully added to your 
